Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company, announced its financial results for the year ended December 31, 2025, highlighting significant progress in its clinical and operational strategies. The company reported cash and cash equivalents of $5.08 million, excluding an additional $7 million from a recent venture debt facility with Avenue Capital Group. This funding is expected to extend the company's financial runway through the end of 2027, allowing for continued investment in its lead investigational drug, GX-03, which is currently in a Phase 2 trial for moderate-to-severe atopic dermatitis. CEO Bradley Burnam emphasized the company's commitment to advancing its therapeutic programs and the potential for revenue generation through a global supply agreement with Medline, which is anticipated to begin in late 2026. The company also announced key leadership appointments, including Dr. Robert Redfield, former CDC Director, and Martin Dewhurst to its board, aimed at enhancing strategic guidance and operational execution. Overall, the results reflect a strong operational execution and a positive outlook for the company's future.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.